The History of Losartan: How the First ARB Changed Cardiology

Losartan was the first angiotensin II receptor blocker approved in the United States, and it opened an entire drug class now taken by millions of people. Its development story spans decades of research, chemical ingenuity and large clinical trials. Our editorial team traces the history of this medication and why it still matters.
The Renin-Angiotensin System Before Losartan
Scientists had been studying the renin-angiotensin system since the late 19th century, when Tigerstedt and Bergman described renin in 1898. By the mid-20th century, angiotensin II was identified as a powerful hormone that constricts blood vessels and stimulates aldosterone release.
The first major therapeutic breakthrough came with ACE inhibitors. Captopril, developed by Squibb and approved by the FDA in 1981, blocked the enzyme that converts angiotensin I into angiotensin II. It proved highly effective for hypertension and heart failure.
ACE inhibitors had a drawback, however. Because the same enzyme also breaks down bradykinin, many patients developed a persistent dry cough, and a small number experienced angioedema, a potentially dangerous swelling.
Researchers reasoned that blocking angiotensin II directly at its receptor might provide the benefits of ACE inhibition while avoiding bradykinin-related side effects. Early peptide blockers such as saralasin worked but had to be injected and behaved partly like agonists.
From Takeda Leads to DuP 753
In the early 1980s, Japanese company Takeda patented imidazole-5-acetic acid derivatives, including S-8307 and S-8308, that weakly blocked angiotensin II receptors. These compounds were far from drug-ready, but they showed that small, non-peptide molecules could do the job.
A team at DuPont, including Pieter Timmermans, David Carini and John Duncia, used these leads as a starting point. Through systematic modification, they improved potency and oral absorption, eventually introducing a biphenyl tetrazole structure.
The result was DuP 753, later named losartan. Duncia and colleagues described its discovery in a 1992 review, and Timmermans and colleagues (1993) summarized the pharmacology of angiotensin II receptors and their antagonists.
An important discovery was that losartan is converted in the liver into E-3174, a more potent and longer-acting metabolite responsible for much of the clinical effect. This helped explain why once-daily dosing was practical.

Approval and Landmark Trials
Developed in partnership between DuPont and Merck, losartan was approved by the FDA in 1995 under the brand name Cozaar, followed by a combination with hydrochlorothiazide (Hyzaar). It became the first member of the "sartan" class on the US market.
| Trial | Year published | Population | Key finding |
|---|---|---|---|
| RENAAL (Brenner et al.) | 2001 | Type 2 diabetes with nephropathy | Slowed progression of kidney disease |
| LIFE (Dahlöf et al.) | 2002 | Hypertension with left ventricular hypertrophy | Fewer strokes than with atenolol at similar BP |
| Pediatric Heart Network (Lacro et al.) | 2014 | Children and young adults with Marfan syndrome | No advantage over atenolol for aortic growth |
RENAAL helped establish ARBs as kidney-protective agents in diabetes, and losartan received an FDA indication for diabetic nephropathy. LIFE supported an indication for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Clinicians appreciated the drug's tolerability. Cough rates were similar to placebo, making losartan a common alternative for patients who could not tolerate ACE inhibitors.
Unexpected Research Paths: Marfan Syndrome and Muscle
In 2006, Habashi and colleagues published a study in Science showing that losartan prevented aortic aneurysm in a mouse model of Marfan syndrome by blocking TGF-beta signaling. The finding created great excitement among patients and families.
Large human trials followed. The Pediatric Heart Network study (Lacro et al., 2014) found that losartan was not superior to atenolol in slowing aortic root dilation, although both were reasonably effective. The story illustrated how animal breakthroughs must be tested carefully in people.
Researchers also explored losartan's effect on skeletal muscle. Burks and colleagues (2011) reported in mice that losartan improved muscle remodeling and protected against disuse atrophy in aged animals, again through TGF-beta pathways. These findings are experimental and do not justify off-label use by athletes.
Investigations into muscle repair, fibrosis and sports injuries continue, but human evidence remains limited. Using a prescription antihypertensive without indication can cause low blood pressure, dizziness and kidney problems.
Generics, Recalls and Losartan Today
- 2010: generic losartan became available in the US, dramatically lowering cost.
- 2018–2019: several lots of sartans, including losartan, were recalled after detection of nitrosamine impurities such as NDEA and NMBA linked to manufacturing processes.
- After the recalls: the FDA set interim acceptable intake limits and required manufacturers to evaluate and control nitrosamine risks.
- Today: losartan remains among the most prescribed blood pressure drugs in the United States.
The nitrosamine recalls highlighted vulnerabilities in global pharmaceutical supply chains. Patients were advised not to stop their medication abruptly but to contact their pharmacist or physician for a replacement.
Modern hypertension guidelines from the American College of Cardiology and American Heart Association list ARBs among first-line options. For many patients, losartan is chosen because of its long track record, low cost and favorable side-effect profile.
Losartan is contraindicated in pregnancy, and like other RAAS blockers it requires monitoring of potassium and kidney function, particularly when combined with diuretics or NSAIDs.
Editorial Team Conclusions
Losartan grew out of decades of research into the renin-angiotensin system and a clever chemical modification of Takeda's early leads. Its 1995 approval launched the ARB class.
Landmark trials established its value in diabetic kidney disease and in hypertension with heart enlargement, while research on Marfan syndrome and muscle showed both the promise and limits of extrapolating from animals.
Readers may also like our articles on losartan drug interactions, how blood pressure medications affect exercise, and the history of ACE inhibitors.
References
- Duncia JV, Carini DJ, Chiu AT, et al. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev. 1992;12(2):149–191.
- Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45(2):205–251.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
- Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
- Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–121.
- Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061–2071.
- Burks TN, Andres-Mateos E, Marx R, et al. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med. 2011;3(82):82ra37.
- https://testolabmilano.com/injectable-steroids/trenbolone/


